Skip to main content

Table 3 List of antibodies used

From: Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein–Barr virus infection in Nigeria population

ANTIBODY

COMPANY

CLONE

DILUTION

Bcl-2

Roche Ventana

SP66

ready to use

Bcl-6

Cell Marque

GI191E/A8

1:50

CD 10

Roche Ventana

SP67

ready to use

CD 138

Roche Ventana

B-A38

ready to use

CD 15

Roche Ventana

MMA

ready to use

CD 20

Roche Ventana

L-26

ready to use

CD 21

Roche Ventana

2G9

ready to use

CD 23

Roche Ventana

SP23

ready to use

CD 3

Roche Ventana

2GV6

ready to use

CICLINA D

Roche Ventana

SP4-R

ready to use

C-MYC

Roche Ventana

EP121

ready to use

HHV8

Roche Ventana

13B10

ready to use

KAPPA

Cell Marque

L1C1

1:20

KI-67

Roche Ventana

30 9

ready to use

LAMBDA

Cell Marque

LAMB14

1:50

IGA

Cell Marque

2652

1:50

IGG

Cell Marque

2653

1:50

IGM

Cell Marque

2654

1:50

PAX5

Roche Ventana

SP34

ready to use

PD-1

Cell Marque

NAT105

1:20

S-100

Roche Ventana

4C4.9

ready to use

TDT

Cell Marque

TDT

1:100